* enVVeno Medical Corp NVNO.OQ NVNO.O is expected
to show no
change in quarterly revenue when it reports results
*
* Refinitiv's mean analyst estimate for enVVeno Medical
Corp is
for a loss of 48 cents per share.
* The one available analyst rating on the shares is "strong
buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for enVVeno
Medical
Corp is $20.4, above its last closing price of $5.48.
This summary was machine generated October 20 at 20:43 GMT. All
figures in US dollars unless otherwise stated